

2/32

MET_50	20.352079	89.4386316	1	1
ASP_51	140.46051	77.095856	1	0
VAL_52	59.019928	65.664336	1	0
ASP_53	57.198666	72.8180802	1	0
LEU_54	51.290497	45.9930286	0	0
SER_55	56.1208	49.3437382	0	0
THR_56	6.335252	47.723164	0	0
ALA_57	75.773476	43.8934994	0	0
SER_58	49.095795	51.656078	1	0
THR_59	32.142174	59.4056414	1	0
THR_60	94.933693	72.6291262	1	0
GLN_61	45.083069	73.3905916	1	0 P2
GLU_62	141.8909	99.7907822	1	1
GLY_63	52.903122	90.626043	1	1
GLU_64	164.143127	83.4067496	1	1
LEU_65	49.109997	57.2201384	1	0
ALA_66	8.986602	47.5504318	0	0
SER_67	10.957844	17.0083172	0	0
THR_68	4.554589	7.3021006	0	0
GLN_69	11.432554	7.2534874	0	0
SER_70	0.578914	5.0619186	0	0
GLU_71	8.743536	8.9567614	0	0
LEU_72	0	10.8120506	0	0
THR_73	24.028803	23.2812776	0	0
LEU_74	20.709	37.264713	0	0
SER_75	62.925049	69.375269	1	0
GLN_76	78.660713	79.6644746	1	0
LYS_77	160.55278	78.1594206	1	0
HIS_78	75.474831	77.9196576	1	0
TRP_79	13.18373	76.6092892	1	0 P3
LEU_80	61.726234	70.354977	1	0
SER_81	72.108871	73.244224	1	0
ASP_82	129.281219	81.9731098	1	1
ARG_83	89.921066	69.9061278	1	0
THR_84	56.828159	58.6259284	1	0
TYR_85	1.391324	32.7696846	0	0
THR_86	15.707874	23.8688072	0	0
CYS_87	0	12.5031754	0	0
GLN_88	45.416679	24.6922706	0	0
VAL_89	0	22.314276	0	0
THR_90	62.3368	48.4045714	0	0
TYR_91	3.817901	45.5941352	0	0
GLN_92	130.451477	47.9061642	0	0
GLY_93	31.364498	62.7324992	1	0
HIS_94	11.560145	91.805003	1	1
THR_95	136.468475	85.5324108	1	1
PHE_96	149.18042	87.190961	1	1
GLU_97	99.088516	90.6138422	1	1
ASP_98	39.657249	75.8683994	1	0
SER_99	28.674551	62.1985202	1	0
THR_100	62.741261	62.538042	1	0
LYS_101	80.831024	61.892236	1	0
LYS_102	100.786125	65.3434144	1	0 P4
CYS_103	36.428219	66.2248162	1	0
ALA_104	45.930443	63.0386422	1	0
ASP_105	67.14827	64.611715	1	0

3/32

WO 00/50460

SER\_106


64.900154

71.4769134

1

0


4/32

**Fig. 2** Scheme 1, solid phase peptide synthesisScheme 1


5/32


**Fig. 3** Modified carrier preparation

Scheme 2




Scheme 3







7/32

**Fig. 5** C67-8 Anti-IgE Data

8/32


**Fig. 6** Competition assay with soluble IgE and IgE C67-8 peptide.

9/32


**Fig. 7** PT1079 Anti-IgE Data




10/32

**Fig. 8** Competition assay with soluble IgE and PT1079 peptide.

11/32


**Fig. 9** PT1078 Anti-IgE Data

12/32



**Fig. 10** Competition assay with soluble IgE and PT1078 peptide.

13/32



**Fig. 11** PT1079gs Anti-IgE Data



14/32



**Fig. 12** Competition assay with soluble IgE and PT1079 peptide.**Fig. 13** Inhibitory Activity of Mouse BSA-C67-8 induced Antisera

15/32

**Fig. 14** Inhibitory Activity of Mouse Antisera induced by BSA-1078 and BSA-1079.**Fig.15** Inhibitory Activity of Mouse Antisera induced by HBC-C67-8, HBC-1078, HBC-1079 and HBC-1079gs



16/32

**Fig. 16** shows the concentration dependent binding of antibody PTmAb0005 and PTmAb0011 to IgE.



17/32



**Fig. 17** shows the concentration dependent inhibition of IgE binding to an Fc $\epsilon$ R1 $\alpha$ /IgG construct with antibody PTmAb0005 and PTmAb0011 compared to control.







18/32

**Fig. 18** shows the concentration dependent inhibition of IgE binding to clipped ectodomain of Fc $\epsilon$ R1 $\alpha$ -bound directly to plastic plates, by antibody PTmAb0005, compared to control.





19/32

**Fig. 19** shows IgE binding to Fc $\epsilon$ RII (CD23) by antibody PTmAb0005 (GE-1) and PTmAb0011.



20/32


**Fig. 20** shows the concentration-dependent blocking of histamine release from allergic human blood basophils with antibody PTmAb0005 and PTmAb0011 compared to control.





21/32

**Fig. 21**



Inhibition of LoIP1-Triggered  
Histamine Release in Allergic  
Human Basophils





22/32

**Fig. 22** PTmAb0011 binding to different IgE.**A. Chimaeric IgE****B. Binding to Myeloma IgE**

23/32



**Fig. 22****C. Binding to Antigen Orientated IgE****D. Binding to Heat Denatured IgE**

24/32

**Fig. 23** Inhibition of IgE Binding to Fc $\epsilon$ R1 $\alpha$  by PTmAb0011.**Fig. 24** Binding of PTmAb0011 to Receptor Bound IgE.

25/32


**Fig. 25** The effect of PTmAb0011 on IgE binding to FcεRII on RPMI 8866 cells.






26/32

**Fig. 26** Analysis of the effects of PTmAb0011 on IgE binding to FcεRII on primary human B-cells.




27/32

**Fig. 27** Effects of PTmAb0011 on IgE secretion from primary human B-cells.





28/32

**Fig. 28** Anaphylactogenicity of anti-human IgE monoclonal antibodies in allergic (A) and non-allergic (B) human basophils




29/32

**Fig. 29** Anaphylactogenicity of anti-human IgE antibodies in sensitised (A) and non-sensitised (B) human lung mast cells





30/32

**Fig. 30** Anaphylactogenicity of anti-human IgE antibodies in RBL J41 cells through human Fc $\epsilon$ RI (A) and mouse Fc $\epsilon$ RI (B)




31/32

**Fig. 31** Inhibition of allergen-triggered histamine release in human basophils by PTmAb0011



32/32

**Fig. 32** Inhibition of passive cutaneous anaphylaxis in Monkey skin by PTmAb0011 and PTmAb0005.



## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Epitopes or mimotopes derived from the C-Epsilon-2 domain of IGE, antagonists thereof, and their therapeutic uses

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 22 February 2000 as Serial No. PCT/EP00/01455  
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)				
Number	Country	Filing Date	Priority Claimed	
9907151.6	GB	29/03/1999	Yes	<del>No</del>
9910537.1	GB	07/05/1999	Yes	No
9910538.9	GB	07/05/1999	Yes	No
9918594.4	GB	07/08/1999	Yes	No
9918603.3	GB	07/08/1999	Yes	No
9921046.0	GB	07/09/1999	Yes	No
9921047.8	GB	07/09/1999	Yes	No
9925619.0	GB	29/10/1999	Yes	No
9927698.2	GB	23/11/1999	Yes	No

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section

091409-11 650460



## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Epitopes or mimotopes derived from the C-Epsilon-2 domain of IGE, antagonists thereof, and their therapeutic uses

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 22 February 2000 as Serial No. PCT/EP00/01455  
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
9907151.6	GB	29/03/1999	Yes <del>No</del>
9910537.1	GB	07/05/1999	Yes No
9910538.9	GB	07/05/1999	Yes No
9918594.4	GB	07/08/1999	Yes No
9918603.3	GB	07/08/1999	Yes No
9921046.0	GB	07/09/1999	Yes No
9921047.8	GB	07/09/1999	Yes No
9925619.0	GB	29/10/1999	Yes No
9927698.2	GB	23/11/1999	Yes No

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section

112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to \_\_\_\_\_, SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-EEE.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Michael DYSON

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Martin FRIEDE

Inventor's Signature: Martin Friede Date: 28 Sept 01

Residence: Cardiff, California, USA

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Judith GREENWOOD

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Ellen HEWITT

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Royston, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Alan LAMONT

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Croydon, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939



[illegible]

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Epitopes or mimotopes derived from the C-Epsilon-2 domain of IGE, antagonists thereof, and their therapeutic uses

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 22 February 2000 as Serial No. PCT/EP00/01455  
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			
Number	Country	Filing Date	Priority Claimed
9907151.6	GB	29/03/1999	Yes
9910537.1	GB	07/05/1999	Yes No
9910538.9	GB	07/05/1999	Yes No
9918594.4	GB	07/08/1999	Yes No
9918603.3	GB	07/08/1999	Yes No
9921046.0	GB	07/09/1999	Yes No
9921047.8	GB	07/09/1999	Yes No
9925619.0	GB	29/10/1999	Yes No
9927698.2	GB	23/11/1999	Yes No

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section

09974088 440047660

112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to \_\_\_\_\_, SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-EEE.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Michael DYSON

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Martin FRIEDE

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cardiff, California, USA

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Judith GREENWOOD

Inventor's Signature: Judith Greenwood Date: 2/10/01

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Ellen HEWITT

Inventor's Signature: Ellen Hewitt Date: 2nd Oct 01

Residence: Royston, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Alan LAMONT

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Croydon, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939



Full Name of Inventor: Sean MASON

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Roger RANDALL

Inventor's Signature: Randall Date: 2nd Oct 2001

Residence: Colne, Huntingdon, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: William Gordon TURNELL

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

09974088.11304  
FOEFF 8804660

Year	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	

Residence: Wagnelee, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Carlotta VINALS y de BASSOLS

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Brussels, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Epitopes or mimotopes derived from the C-Epsilon-2 domain of IGE, antagonists thereof, and their therapeutic uses

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 22 February 2000 as Serial No. PCT/EP00/01455  
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed	
9907151.6	GB	29/03/1999	Yes	<del>No</del>
9910537.1	GB	07/05/1999	Yes	No
9910538.9	GB	07/05/1999	Yes	No
9918594.4	GB	07/08/1999	Yes	No
9918603.3	GB	07/08/1999	Yes	No
9921046.0	GB	07/09/1999	Yes	No
9921047.8	GB	07/09/1999	Yes	No
9925619.0	GB	29/10/1999	Yes	No
9927698.2	GB	23/11/1999	Yes	No

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section

PCT/EP00/01455

112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to \_\_\_\_\_, SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-EEE.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Michael DYSON

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Martin FRIEDE

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cardiff, California, USA

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

1992-1993 1994-1995 1996-1997 1998-1999 2000-2001 2002-2003 2004-2005 2006-2007 2008-2009 2010-2011 2012-2013 2014-2015 2016-2017 2018-2019 2020-2021 2022-2023 2024-2025 2026-2027 2028-2029 2030-2031 2032-2033 2034-2035 2036-2037 2038-2039 2040-2041 2042-2043 2044-2045 2046-2047 2048-2049 2050-2051 2052-2053 2054-2055 2056-2057 2058-2059 2060-2061 2062-2063 2064-2065 2066-2067 2068-2069 2070-2071 2072-2073 2074-2075 2076-2077 2078-2079 2080-2081 2082-2083 2084-2085 2086-2087 2088-2089 2090-2091 2092-2093 2094-2095 2096-2097 2098-2099 2100-2101 2102-2103 2104-2105 2106-2107 2108-2109 2110-2111 2112-2113 2114-2115 2116-2117 2118-2119 2120-2121 2122-2123 2124-2125 2126-2127 2128-2129 2130-2131 2132-2133 2134-2135 2136-2137 2138-2139 2140-2141 2142-2143 2144-2145 2146-2147 2148-2149 2150-2151 2152-2153 2154-2155 2156-2157 2158-2159 2160-2161 2162-2163 2164-2165 2166-2167 2168-2169 2170-2171 2172-2173 2174-2175 2176-2177 2178-2179 2180-2181 2182-2183 2184-2185 2186-2187 2188-2189 2190-2191 2192-2193 2194-2195 2196-2197 2198-2199 2200-2201 2202-2203 2204-2205 2206-2207 2208-2209 2210-2211 2212-2213 2214-2215 2216-2217 2218-2219 2220-2221 2222-2223 2224-2225 2226-2227 2228-2229 2230-2231 2232-2233 2234-2235 2236-2237 2238-2239 2240-2241 2242-2243 2244-2245 2246-2247 2248-2249 2250-2251 2252-2253 2254-2255 2256-2257 2258-2259 2260-2261 2262-2263 2264-2265 2266-2267 2268-2269 2270-2271 2272-2273 2274-2275 2276-2277 2278-2279 2280-2281 2282-2283 2284-2285 2286-2287 2288-2289 2290-2291 2292-2293 2294-2295 2296-2297 2298-2299 2300-2301 2302-2303 2304-2305 2306-2307 2308-2309 2310-2311 2312-2313 2314-2315 2316-2317 2318-2319 2320-2321 2322-2323 2324-2325 2326-2327 2328-2329 2330-2331 2332-2333 2334-2335 2336-2337 2338-2339 2340-2341 2342-2343 2344-2345 2346-2347 2348-2349 2350-2351 2352-2353 2354-2355 2356-2357 2358-2359 2360-2361 2362-2363 2364-2365 2366-2367 2368-2369 2370-2371 2372-2373 2374-2375 2376-2377 2378-2379 2380-2381 2382-2383 2384-2385 2386-2387 2388-2389 2390-2391 2392-2393 2394-2395 2396-2397 2398-2399 2400-2401 2402-2403 2404-2405 2406-2407 2408-2409 2410-2411 2412-2413 2414-2415 2416-2417 2418-2419 2420-2421 2422-2423 2424-2425 2426-2427 2428-2429 2430-2431 2432-2433 2434-2435 2436-2437 2438-2439 2440-2441 2442-2443 2444-2445 2446-2447 2448-2449 2450-2451 2452-2453 2454-2455 2456-2457 2458-2459 2460-2461 2462-2463 2464-2465 2466-2467 2468-2469 2470-2471 2472-2473 2474-2475 2476-2477 2478-2479 2480-2481 2482-2483 2484-2485 2486-2487 2488-2489 2490-2491 2492-2493 2494-2495 2496-2497 2498-2499 2500-2501 2502-2503 2504-2505 2506-2507 2508-2509 2510-2511 2512-2513 2514-2515 2516-2517 2518-2519 2520-2521 2522-2523 2524-2525 2526-2527 2528-2529 2530-2531 2532-2533 2534-2535 2536-2537 2538-2539 2540-2541 2542-2543 2544-2545 2546-2547 2548-2549 2550-2551 2552-2553 2554-2555 2556-2557 2558-2559 2560-2561 2562-2563 2564-2565 2566-2567 2568-2569 2570-2571 2572-2573 2574-2575 2576-2577 2578-2579 2580-2581 2582-2583 2584-2585 2586-2587 2588-2589 2590-2591 2592-2593 2594-2595 2596-2597 2598-2599 2600-2601 2602-2603 2604-2605 2606-2607 2608-2609 2610-2611 2612-2613 2614-2615 2616-2617 2618-2619 2620-2621 2622-2623 2624-2625 2626-2627 2628-2629 2630-2631 2632-2633 2634-2635 2636-2637 2638-2639 2640-2641 2642-2643 2644-2645 2646-2647 2648-2649 2650-2651 2652-2653 2654-2655 2656-2657 2658-2659 2660-2661 2662-2663 2664-2665 2666-2667 2668-2669 2670-2671 2672-2673 2674-2675 2676-2677 2678-2679 2680-2681 2682-2683 2684-2685 2686-2687 2688-2689 2690-2691 2692-2693 2694-2695 2696-2697 2698-2699 2700-2701 2702-2703 2704-2705 2706-2707 2708-2709 2710-2711 2712-2713 2714-2715 2716-2717 2718-2719 2720-2721 2722-2723 2724-2725 2726-2727 2728-2729 2730-2731 2732-2733 2734-2735 2736-2737 2738-2739 2740-2741 2742-2743 2744-2745 2746-2747 2748-2749 2750-2751 2752-2753 2754-2755 2756-2757 2758-2759 2760-2761 2762-2763 2764-2765 2766-2767 2768-2769 2770-2771 2772-2773 2774-2775 2776-2777 2778-2779 2780-2781 2782-2783 2784-2785 2786-2787 2788-2789 2790-2791 2792-2793 2794-2795 2796-2797 2798-2799 2800-2801 2802-2803 2804-2805 2806-2807 2808-2809 2

Residence: Cambridge, United Kingdom

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Royston, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Inventor's Signature: [Signature] Date: 17 SEPT 01

Residence: Croydon, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Sean MASON

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Roger RANDALL

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Colne, Huntingdon, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: William Gordon TURNELL

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Marcelle Paulette VAN MECHELEN

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Wagnelee, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Carlotta VINALS y de BASSOLS

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Brussels, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

100-11-554150

## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Epitopes or mimotopes derived from the C-Epsilon-2 domain of IGE, antagonists thereof, and their therapeutic uses

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 22 February 2000 as Serial No. PCT/EP00/01455  
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			
Number	Country	Filing Date	Priority Claimed
9907151.6	GB	29/03/1999	Yes <del>No</del>
9910537.1	GB	07/05/1999	Yes No
9910538.9	GB	07/05/1999	Yes No
9918594.4	GB	07/08/1999	Yes No
9918603.3	GB	07/08/1999	Yes No
9921046.0	GB	07/09/1999	Yes No
9921047.8	GB	07/09/1999	Yes No
9925619.0	GB	29/10/1999	Yes No
9927698.2	GB	23/11/1999	Yes No

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section

PCT/EP00/01455



112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to \_\_\_\_\_, SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-EEE.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Michael DYSON

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Martin FRIEDE

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cardiff, California, USA

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

1900	1901	1902	1903	1904	1905	1906	1907	1908	1909	1910	1911	1912	1913	1914	1915	1916	1917	1918	1919	1920	1921	1922	1923	1924	1925	1926	1927	1928	1929	1930	1931	1932	1933	1934	1935	1936	1937	1938	1939	1940	1941	1942	1943	1944	1945	1946	1947	1948	1949	1950	1951	1952	1953	1954	1955	1956	1957	1958	1959	1960	1961	1962	1963	1964	1965	1966	1967	1968	1969	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1900	1901	1902	1903	1904	1905	1906	1907	1908	1909	1910	1911	1912	1913	1914	1915	1916	1917	1918	1919	1920	1921	1922	1923	1924	1925	1926	1927	1928	1929	1930	1931	1932	1933	1934	1935	1936	1937	1938	1939	1940	1941	1942	1943	1944	1945	1946	1947	1948	1949	1950	1951	1952	1953	1954	1955	1956	1957	1958	1959	1960	1961	1962	1963	1964	1965	1966	1967	1968	1969	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100

Residence: Cambridge, United Kingdom

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

1. The first step is to identify the problem. This involves understanding the symptoms and the context in which they are occurring.

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939



## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Epitopes or mimotopes derived from the C-Epsilon-2 domain of IGE, antagonists thereof, and their therapeutic uses

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 22 February 2000 as Serial No. PCT/EP00/01455  
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed	
9907151.6	GB	29/03/1999	Yes	<del>No</del>
9910537.1	GB	07/05/1999	Yes	No
9910538.9	GB	07/05/1999	Yes	No
9918594.4	GB	07/08/1999	Yes	No
9918603.3	GB	07/08/1999	Yes	No
9921046.0	GB	07/09/1999	Yes	No
9921047.8	GB	07/09/1999	Yes	No
9925619.0	GB	29/10/1999	Yes	No
9927698.2	GB	23/11/1999	Yes	No

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section

09914033-11301

112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to \_\_\_\_\_, SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-EEE.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Michael DYSON

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Martin FRIEDE

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cardiff, California, USA

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Judith GREENWOOD

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Ellen HEWITT

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Royston, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Alan LAMONT

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Croydon, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

0991408 11304  
TCEFF 82041560

Full Name of Inventor: Sean MASON

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Roger RANDALL

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Colne, Huntingdon, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: William Gordon TURNELL

Inventor's Signature: Bill Turnell Date: 10<sup>th</sup> Sept. 2001

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939



Full Name of Inventor: Marcelle Paulette VAN MECHELEN

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Wagnelee, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Carlotta VINALS y de BASSOLS

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Brussels, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

09044033 111304  
T0211 88041550

## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Epitopes or mimotopes derived from the C-Epsilon-2 domain of IGE, antagonists thereof, and their therapeutic uses

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 22 February 2000 as Serial No. PCT/EP00/01455  
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed	
9907151.6	GB	29/03/1999	Yes	<del>No</del>
9910537.1	GB	07/05/1999	Yes	No
9910538.9	GB	07/05/1999	Yes	No
9918594.4	GB	07/08/1999	Yes	No
9918603.3	GB	07/08/1999	Yes	No
9921046.0	GB	07/09/1999	Yes	No
9921047.8	GB	07/09/1999	Yes	No
9925619.0	GB	29/10/1999	Yes	No
9927698.2	GB	23/11/1999	Yes	No

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section

09914088 11301

112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to \_\_\_\_\_, SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-EEE.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Michael DYSON

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Martin FRIEDE

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cardiff, California, USA

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Judith GREENWOOD

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Ellen HEWITT

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Royston, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Alan LAMONT

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Croydon, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Sean MASON

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Roger RANDALL

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Colne, Huntingdon, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: William Gordon TURNELL

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

FOOTNOTES

Full Name of Inventor: Marcelle Paulette VAN MECHELEN

Inventor's Signature: Van Mechelen Date: 11<sup>th</sup> September 01

Residence: Wagnelee, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Carlotta VINALS y de BASSOLS

Inventor's Signature: Carlotta Vinals Date: 14.09.01

Residence: Brussels, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

0944033-4404  
10444 88044650

112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to \_\_\_\_\_, SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-EEE.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Michael DYSON

Inventor's Signature: M.R. Dyson Date: 6.9.01

Residence: Cambridge, United Kingdom GBX

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Martin FRIEDE

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cardiff, California, USA CA

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Judith GREENWOOD

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom GBX

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Ellen HEWITT

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Royston, Hertfordshire, United Kingdom GBX

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Alan LAMONT

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Croydon, Hertfordshire, United Kingdom GBX

Citizenship: British

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939



Full Name of Inventor: Sean MASON

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

GBX

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Roger RANDALL

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Colne, Huntingdon, United Kingdom

Citizenship: British

GBX

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: William Gordon TURNELL

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: Cambridge, United Kingdom

Citizenship: British

GBX

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

90

BEX

BEX

BEX

BEX

100-15600-100

EX

EX

EX

EX

09/914088

PCT/EP00/01455

WO 00/50460

## SEQUENCE LISTING

5           <110> SmithKline Beecham Biologicals s.a.  
            Peptide Therapeutics

            <120> Vaccine

10           <130> B45172

            <160> 193

            <170> FastSEQ for Windows Version 3.0

15           <210> 1  
            <211> 9  
            <212> PRT  
            <213> Human and artificial sequences

20           <400> 1  
Glu Asp Gly Gln Val Met Asp Val Asp  
  1                          5

25           <210> 2  
            <211> 8  
            <212> PRT  
            <213> Human and artificial sequences

30           <400> 2  
Ser Thr Thr Gln Glu Gly Glu Leu  
  1                          5

35           <210> 3  
            <211> 10  
            <212> PRT  
            <213> Human and artificial sequences

40           <400> 3  
Ser Gln Lys His Trp Leu Ser Asp Arg Thr  
  1                          5                  10

45           <210> 4  
            <211> 10  
            <212> PRT  
            <213> Human and artificial sequences

50           <400> 4  
Gly His Thr Phe Glu Asp Ser Thr Lys Lys  
  1                          5                  10

55           <210> 5  
            <211> 8  
            <212> PRT  
            <213> Human and artificial sequences

60           <400> 5  
Gly Gly Gly His Phe Pro Pro Thr  
  1                          5

65           <210> 6  
            <211> 6  
            <212> PRT  
            <213> Human and artificial sequences

            <400> 6

Pro Gly Thr Ile Asn Ile  
1 5

5 <210> 7  
<211> 5  
<212> PRT  
<213> Human and artificial sequences

10 <400> 7  
Phe Thr Pro Pro Thr  
1 5

15 <210> 8  
<211> 13  
<212> PRT  
<213> Human and artificial sequences

20 <400> 8  
Cys Leu Glu Asp Gly Gln Val Met Asp Val Asp Leu Leu  
1 5 10

25 <210> 9  
<211> 13  
<212> PRT  
<213> Human and artificial sequences

30 <400> 9  
Leu Leu Asp Val Asp Met Val Gln Gly Asp Glu Leu Cys  
1 5 10

35 <210> 10  
<211> 13  
<212> PRT  
<213> Human and artificial sequences

40 <400> 10  
Trp Leu Glu Asp Gly Gln Val Met Asp Val Asp Leu Cys  
1 5 10

45 <210> 11  
<211> 13  
<212> PRT  
<213> Human and artificial sequences

50 <400> 11  
Cys Leu Glu Asp Gly Gln Val Met Asp Val Asp Leu Cys  
1 5 10

55 <210> 12  
<211> 16  
<212> PRT  
<213> Human and artificial sequences

60 <400> 12  
Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu Leu Cys Pro Arg Glu  
1 5 10 15

65 <210> 13  
<211> 16  
<212> PRT  
<213> Human and artificial sequences

<400> 13  
Cys Phe Met Asn Lys Gln Leu Ala Asp Leu Glu Leu Cys Pro Arg Glu  
1 5 10 15

<210> 14  
 <211> 22  
 <212> PRT  
 <213> Human and artificial sequences

5

<400> 14  
 Cys Leu Glu Asp Gly Gln Val Met Asp Val Asp Leu Cys Pro Arg Glu  
 1 5 10 15  
 Ala Ala Glu Gly Asp Lys  
 20

10

<210> 15  
 <211> 20  
 <212> PRT  
 <213> Human and artificial sequences

15

<400> 15  
 Cys Leu Glu Asp Gly Gln Val Met Asp Val Asp Leu Cys Gly Gly Ser  
 1 5 10 15  
 Ser Gly Gly Pro  
 20

20

<210> 16  
 <211> 21  
 <212> PRT  
 <213> Human and artificial sequences

25

<400> 16  
 Cys Leu Glu Asp Gly Gln Val Met Asp Val Asp Cys Pro Arg Glu Ala  
 1 5 10 15  
 Ala Glu Gly Asp Lys  
 20

30

<210> 17  
 <211> 7  
 <212> PRT  
 <213> Human and artificial sequences

35

<400> 17  
 Gln Val Met Asp Val Asp Leu  
 1 5

40

<210> 18  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

45

<400> 18  
 Lys Cys Arg Glu Val Trp Leu Gly Glu Ser Glu Thr Ile Met Asp Cys  
 1 5 10 15  
 Glu

50

<210> 19  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

55

<400> 19  
 Ala Cys Arg Glu Val Trp Leu Gly Glu Ser Glu Thr Ile Met Asp Cys  
 1 5 10 15  
 Asp

60

<210> 20  
 <211> 17

65

&lt;212&gt; PRT

&lt;213&gt; Human and artificial sequences

&lt;400&gt; 20

5 Ser Cys Arg Glu Val Trp Leu Gly Glu Ser Glu Thr Val Met Asp Cys  
 1 5 10 15  
 Gly

10

&lt;210&gt; 21

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Human and artificial sequences

15

&lt;400&gt; 21

Asn Cys Gln Asp Leu Met Leu Arg Glu Asp Ala Gly Cys Trp Ser Lys  
 1 5 10 15  
 Met

20

&lt;210&gt; 22

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Human and artificial sequences

25

&lt;400&gt; 22

Asp Cys Glu Glu Pro Met Cys Ser Pro Val Leu Leu Gln Gln Leu Lys  
 1 5 10 15  
 Leu

30

&lt;210&gt; 23

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Human and artificial sequences

35

&lt;400&gt; 23

Leu Glu Asp Gly Gln Val Met Asp Val Asp  
 1 5 10

40

&lt;210&gt; 24

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Human and artificial sequences

45

&lt;400&gt; 24

Cys Ser Thr Thr Gln Glu Gly Glu Leu Ala  
 1 5 10

50

&lt;210&gt; 25

&lt;211&gt; 6

&lt;212&gt; PRT

&lt;213&gt; Human and artificial sequences

55

&lt;400&gt; 25

Thr Thr Gln Glu Gly Glu  
 1 5

60

&lt;210&gt; 26

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Human and artificial sequences

65

&lt;400&gt; 26

Cys Ser Gln Lys His Trp Leu Ser Asp Arg Thr  
 1 5 10

5           <210> 27  
           <211> 22  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 27  
 Thr Tyr Gln Gly His Thr Phe Glu Asp Ser Thr Lys Lys Cys Ala Asp  
       1                          5                          10                          15  
 10 Ser Asn Pro Arg Gly Val  
           20  
  
           <210> 28  
           <211> 6  
 15           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 28  
 Gly Gly His Phe Pro Pro  
       1                          5  
 20  
  
           <210> 29  
           <211> 13  
           <212> PRT  
 25           <213> Human and artificial sequences  
  
           <400> 29  
 Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu Leu Cys  
       1                          5                          10  
 30  
  
           <210> 30  
           <211> 13  
           <212> PRT  
           <213> Human and artificial sequences  
 35  
  
           <400> 30  
 Cys Phe Met Asn Lys Gln Leu Ala Asp Leu Glu Leu Cys  
       1                          5                          10  
 40  
  
           <210> 31  
           <211> 16  
           <212> PRT  
           <213> Human and artificial sequences  
 45  
  
           <400> 31  
 Lys Cys Arg Glu Val Trp Leu Gly Glu Ser Glu Thr Ile Met Asp Cys  
       1                          5                          10                          15  
 50  
  
           <210> 32  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 32  
 55 His Cys Gln Gln Val Phe Phe Pro Gln Asp Tyr Leu Trp Cys Gln Arg  
       1                          5                          10                          15  
       Gly  
 60  
  
           <210> 33  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequences  
 65  
  
           <400> 33  
 Ser Cys Arg Glu Val Trp Leu Gly Gly Ser Glu Met Ile Met Asp Cys

```

1      5      10      15
Glu

<210> 34
<211> 17
<212> PRT
<213> Human and artificial sequences

<400> 34
Glu Cys Asn Gln Asn Leu Ser Gly Ser Leu Arg His Val Asp Leu Asn
 1      5      10      15
Cys

<210> 35
<211> 17
<212> PRT
<213> Human and artificial sequences

<400> 35
Asp Cys Glu Glu Pro Met Cys Ser Pro Val Leu Leu Gln Lys Leu Lys
 1      5      10      15
Pro

<210> 36
<211> 17
<212> PRT
<213> Human and artificial sequences

<400> 36
Ser Cys Arg Glu Val Trp Leu Gly Gly Ser Glu Met Ile Met Asp Cys
 1      5      10      15
Glu

<210> 37
<211> 17
<212> PRT
<213> Human and artificial sequences

<400> 37
Arg Cys Asp Gln Gln Leu Pro Arg Asp Ser Tyr Thr Phe Cys Met Met
 1      5      10      15
Ser

<210> 38
<211> 17
<212> PRT
<213> Human and artificial sequences

<400> 38
Ser Cys Pro Ala Phe Pro Arg Glu Gly Asp Leu Cys Ala Pro Pro Thr
 1      5      10      15
Val

<210> 39
<211> 17
<212> PRT
<213> Human and artificial sequences

<400> 39
Phe Cys Pro Glu Pro Ile Cys Ser Pro Pro Leu Ser Arg Met Thr Leu

```



```

1
Ser
5
10
15

<210> 40
<211> 12
<212> PRT
<213> Human and artificial sequences

<400> 40
Val Cys Asp Glu Cys Val Ser Arg Glu Leu Ala Leu
1 5 10

<210> 41
<211> 12
<212> PRT
<213> Human and artificial sequences

<400> 41
Trp Cys Leu Glu Pro Glu Cys Ala Pro Gly Leu Leu
1 5 10

<210> 42
<211> 12
<212> PRT
<213> Human and artificial sequences

<400> 42
Val Cys Asp Glu Cys Val Ser Arg Glu Leu Ala Leu
1 5 10

<210> 43
<211> 12
<212> PRT
<213> Human and artificial sequences

<400> 43
Asp Cys Leu Ser Lys Gly Gln Met Ala Asp Leu Cys
1 5 10

<210> 44
<211> 12
<212> PRT
<213> Human and artificial sequences

<400> 44
Ser Cys Gln Gly Arg Glu Val Arg Arg Glu Cys Trp
1 5 10

<210> 45
<211> 17
<212> PRT
<213> Human and artificial sequences

<400> 45
Trp Cys Arg Glu Val Trp Leu Gly Glu Ser Glu Thr Ile Met Asp Cys
1 5 10 15
Glu

<210> 46
<211> 17
<212> PRT
<213> Human and artificial sequences

<400> 46

```

Ala Cys Arg Glu Val Trp Leu Gly Glu Ser Glu Thr Ile Met Asp Cys  
 1 5 10 15  
 Asp

5

<210> 47  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

10

<400> 47  
 Gly Cys Ala Glu Pro Lys Cys Trp Gln Ala Leu His Gln Lys Leu Lys  
 1 5 10 15  
 Pro

15

<210> 48  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

20

<400> 48  
 Glu Cys Arg Gly Pro Asn Met Gln Met Gln Asp His Cys Pro Thr Thr  
 1 5 10 15  
 Asp

25

<210> 49  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

30

<400> 49  
 Gln Cys Asn Ala Val Leu Glu Gly Leu Gln Met Val Asp His Cys Trp  
 1 5 10 15  
 Asn

35

<210> 50  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

40

<400> 50  
 Cys Cys Val Ala Asp Pro Glu Thr Gln Met Thr Pro Ser Ser Glu Met  
 1 5 10 15  
 Phe

45

<210> 51  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

50

<400> 51  
 His Cys Lys Asn Glu Phe Lys Lys Gly Gln Trp Thr Tyr Ser Cys Ser  
 1 5 10 15  
 Asp

55

<210> 52  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

60

<400> 52

65

Gln Cys Arg Gln Phe Val Met Asn Gln Ser Glu Lys Glu Phe Gly Gln  
 1 5 10 15  
 Cys

5

<210> 53  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

10

<400> 53  
 Asn Cys Phe Met Asn Lys Gln Leu Ala Asp Leu Glu Leu Cys Pro Arg  
 1 5 10 15  
 Glu

15

<210> 54  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

20

<400> 54  
 Ser Cys Ala Tyr Thr Ala Gln Arg Gln Cys Ser Asp Val Pro Asn Pro  
 1 5 10 15  
 Gly

25

<210> 55  
 <211> 19  
 <212> PRT  
 <213> Human and artificial sequences

30

<400> 55  
 Gly Cys Phe Met Asn Lys Gln Met Ala Asp Leu Glu Leu Cys Pro Arg  
 1 5 10 15  
 Thr Ala Ala

35

<210> 56  
 <211> 19  
 <212> PRT  
 <213> Human and artificial sequences

40

<400> 56  
 Ala Cys Phe Met Asn Lys Gln Met Ala Asp Leu Glu Leu Cys Pro Arg  
 1 5 10 15  
 Val Ala Ala

45

<210> 57  
 <211> 19  
 <212> PRT  
 <213> Human and artificial sequences

50

<400> 57  
 Gly Cys Phe Ile Asn Lys Gln Leu Ala Asp Leu Glu Leu Cys Pro Arg  
 1 5 10 15  
 Val Ala Ala

55

<210> 58  
 <211> 19  
 <212> PRT  
 <213> Human and artificial sequences

60

<400> 58

65

Gly Cys Phe Met Asn Lys Gln Leu Ala Asp Trp Glu Leu Cys Pro Arg  
 1 5 10 15  
 Ala Ala Ala

5

<210> 59  
 <211> 19  
 <212> PRT  
 <213> Human and artificial sequences

10

<400> 59  
 Glu Cys Phe Met Asn Lys Gln Leu Ala Asp Ser Glu Leu Cys Pro Arg  
 1 5 10 15  
 Val Ala Ala

15

<210> 60  
 <211> 19  
 <212> PRT  
 <213> Human and artificial sequences

20

<400> 60  
 Gly Cys Phe Met Asn Lys Gln Leu Ala Asp Pro Glu Leu Cys Pro Arg  
 1 5 10 15  
 Glu Ala Glu

25

<210> 61  
 <211> 19  
 <212> PRT  
 <213> Human and artificial sequences

30

<400> 61  
 Gly Cys Phe Met Asn Lys Gln Leu Val Asp Leu Glu Leu Cys Pro Arg  
 1 5 10 15  
 Gly Ala Ala

35

<210> 62  
 <211> 19  
 <212> PRT  
 <213> Human and artificial sequences

40

<400> 62  
 Gly Cys Phe Met Asn Lys Gln Leu Ala Asp Leu Glu Leu Cys Pro Arg  
 1 5 10 15  
 Glu Ala Ala

45

<210> 63  
 <211> 19  
 <212> PRT  
 <213> Human and artificial sequences

50

<400> 63  
 Gly Cys Phe Met Asn Lys Gln Gln Ala Asp Leu Glu Leu Cys Pro Arg  
 1 5 10 15  
 Gly Ala Ala

55

<210> 64  
 <211> 19  
 <212> PRT  
 <213> Human and artificial sequences

60

<400> 64

65

Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu Leu Cys Pro Arg  
 1 5 10 15  
 Glu Ala Ala

5

<210> 65  
 <211> 20  
 <212> PRT  
 <213> Human and artificial sequences

10

<400> 65  
 Cys Leu Glu Asp Gly Gln Val Met Asp Val Asp Cys Pro Arg Glu Ala  
 1 5 10 15  
 Ala Glu Gly Asp  
 20

15

<210> 66  
 <211> 21  
 <212> PRT  
 <213> Human and artificial sequences

20

<400> 66  
 Cys Leu Glu Asp Gly Gln Val Met Asp Val Asp Leu Cys Pro Arg Glu  
 1 5 10 15  
 Ala Ala Glu Gly Asp  
 20

25

<210> 67  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

30

<400> 67  
 Gln Cys Asn Ala Val Leu Glu Gly Leu Gln Met Val Asp His Cys Trp  
 1 5 10 15  
 Asn

35

<210> 68  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

40

<400> 68  
 Cys Cys Val Ala Asp Pro Glu Thr Gln Met Thr Pro Ser Ser Glu Met  
 1 5 10 15  
 Phe

45

<210> 69  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

50

<400> 69  
 Glu Cys Leu Lys Ile Glu Gln Gln Cys Ala Asp Ile Val Glu Ile Pro  
 1 5 10 15  
 Arg

55

<210> 70  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

60

<400> 70

65

Ser Cys Ala Tyr Thr Ala Gln Arg Gln Cys Ser Asp Val Pro Asn Pro  
 1 5 10 15  
 Gly

5

<210> 71  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

10

<400> 71  
 Glu Cys Arg Gly Pro Asn Met Gln Met Gln Asp His Cys Pro Thr Thr  
 1 5 10 15  
 Asp

15

<210> 72  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

20

<400> 72  
 Glu Cys Leu Val Tyr Gly Gln Met Ala Asp Cys Ala Ala Gly Gly Trp  
 1 5 10 15  
 Pro

25

<210> 73  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

30

<400> 73  
 Gln Cys Arg Gln Phe Val Met Asn Gln Ser Glu Lys Glu Phe Gly Gln  
 1 5 10 15  
 Cys

35

<210> 74  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

40

<400> 74  
 His Cys Lys Asn Glu Phe Lys Lys Gly Gln Trp Thr Tyr Ser Cys Ser  
 1 5 10 15  
 Asp

45

<210> 75  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

50

<400> 75  
 Cys Cys Val Thr Asp Val Gln Thr Thr Asn Met Asp Val Pro Ala Gly  
 1 5 10 15  
 Gln

55

<210> 76  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

60

<400> 76

65

Thr Cys Cys Val Thr Asp Ile Pro Pro Pro Asp Tyr Glu Gln Ser Leu  
 1 5 10 15  
 Gly

5

<210> 77  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

10

<400> 77  
 Cys Cys Glu Ser Asp Ile Pro Leu Asn Glu Leu His Ala Leu Ala Asp  
 1 5 10 15  
 Pro

15

<210> 78  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

20

<400> 78  
 Cys Cys Lys Ser Asp Ile Pro Ser Pro Val Thr Gln Phe Asn Thr Met  
 1 5 10 15  
 Lys

25

<210> 79  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

30

<400> 79  
 Cys Cys Gln Ser Asp Val Pro His Gln Pro Gly Ile Asn Asp Leu His  
 1 5 10 15  
 Val

35

<210> 80  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

40

<400> 80  
 Cys Cys Met Ser Asp Thr Pro Asp Ile Ser Arg Leu Pro Val Pro Asp  
 1 5 10 15  
 Ser

45

<210> 81  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences

50

<400> 81  
 Cys Cys Met Ser Asp Ser Pro Ala Asp Pro Asn Arg Gly Leu Pro Ile  
 1 5 10 15  
 Trp

55

<210> 82  
 <211> 14  
 <212> PRT  
 <213> Human and artificial sequences

60

<400> 82

65

Cys Cys Leu Ser Asp Asp Ala Pro Thr Leu Pro Val Arg Arg  
 1 5 10

5 <210> 83  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences  
 <400> 83

10 Cys Cys Ile Thr Asp Val Pro Gln Gly Val Met Tyr Lys Gly Ser Pro  
 1 5 10 15  
 Asp

15 <210> 84  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences  
 <400> 84

20 Glu Cys Lys Val Asp Gly Gln Leu Ser Asp Ser Pro Leu Leu Arg Asn  
 1 5 10 15  
 Asn

25 <210> 85  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences  
 <400> 85

30 Cys Cys Met Thr Asp Asp Pro Met Asp Pro Asn Ser Thr Trp Ala Ile  
 1 5 10 15  
 Arg

35 <210> 86  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences  
 <400> 86

40 Cys Cys Met Thr Asp Asp Pro Met Tyr Thr Asn Ser Thr Trp Ala Ile  
 1 5 10 15  
 Arg

45 <210> 87  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences  
 <400> 87

50 Cys Cys Val Asp Asp Thr Pro Asn Ser Gly Leu Ala Met Arg Val Ser  
 1 5 10 15  
 Lys

55 <210> 88  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequences  
 <400> 88

60 Cys Cys Glu Val Asp Asp Phe Pro Thr His His Pro Gly Trp Thr Leu  
 1 5 10 15

65



Arg

5           <210> 89  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 89  
 10   Ser Cys Asn Leu Asn His Gln Ser Cys Asp Ile Pro Pro Val Lys Gln  
       1                       5                       10                       15  
       Ile  
  
 15           <210> 90  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 90  
 20   Cys Cys Met Ala Asp Gln Glu Leu Asp Leu Gly His Asn Ala Ala Asn  
       1                       5                       10                       15  
       Ala  
  
 25           <210> 91  
           <211> 12  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 91  
 30   Cys Cys Val Met Asp Leu Glu Leu Ala Ser Gly Phe  
       1                       5                       10  
  
 35           <210> 92  
           <211> 12  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 92  
 40   Cys Cys Val Met Asp Ile Glu Val Arg Gly Ser Ala  
       1                       5                       10  
  
 45           <210> 93  
           <211> 12  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 93  
 50   Cys Cys Gln Arg Asp Val Glu Leu Val Phe Gly Ser  
       1                       5                       10  
  
           <210> 94  
           <211> 12  
 55           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 94  
 60   Cys Cys Arg Ala Asp Phe Glu Val Gly Asn Gly Gly  
       1                       5                       10  
  
           <210> 95  
           <211> 12  
           <212> PRT  
 65           <213> Human and artificial sequences

<400> 95  
 Cys Cys Val Ser Asp Glu Pro Ala Gly Val Arg Asp  
 1 5 10

5 <210> 96  
 <211> 12  
 <212> PRT  
 <213> Human and artificial sequences

10 <400> 96  
 Gly Ala Gly Trp Gln Glu Lys Asp Lys Glu Leu Arg  
 1 5 10

15 <210> 97  
 <211> 12  
 <212> PRT  
 <213> Human and artificial sequences

20 <400> 97  
 Gly Ala Met Thr Ala Gly Gln Leu Ser Asp Leu Pro  
 1 5 10

25 <210> 98  
 <211> 12  
 <212> PRT  
 <213> Human and artificial sequences

30 <400> 98  
 Val Ala Gly Gly Gln Val Val Asp Arg Glu Leu Lys  
 1 5 10

35 <210> 99  
 <211> 12  
 <212> PRT  
 <213> Human and artificial sequences

40 <400> 99  
 Lys Ala Gly Glu Gln Ala Met Asp Met Glu Leu Arg  
 1 5 10

45 <210> 100  
 <211> 11  
 <212> PRT  
 <213> Human and artificial sequences

50 <400> 100  
 Arg Gly Arg Asn Gln Ile Met Asp Leu Glu Ile  
 1 5 10

55 <210> 101  
 <211> 11  
 <212> PRT  
 <213> Human and artificial sequences

60 <400> 101  
 Gln Ile Asp Arg Gln Ile Thr Asp Thr Leu Leu  
 1 5 10

65 <210> 102  
 <211> 11  
 <212> PRT  
 <213> Human and artificial sequences

<400> 102  
 Arg Glu Gln Gln Ile Ser Asp Val Pro Arg Val  
 1 5 10

5           <210> 103  
           <211> 12  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 103  
 Cys Gln Ala Met Asp Ala Glu Ile Leu Asn Gln Val  
   1                          5                  10  
 10           <210> 104  
           <211> 11  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 104  
 Gly Gln Met Met Asp Thr Glu Leu Leu Asn Arg  
   1                          5                  10  
 15           <210> 105  
           <211> 11  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 105  
 Ser Met Glu Gly Gln Val Arg Asp Ile Gln Val  
   1                          5                  10  
 20           <210> 106  
           <211> 11  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 106  
 Tyr Gln Gln Arg Asp Leu Glu Leu Leu Ala Glu  
   1                          5                  10  
 25           <210> 107  
           <211> 11  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 107  
 Ser Met Gly Gln Lys Val Asp Arg Glu Leu Val  
   1                          5                  10  
 30           <210> 108  
           <211> 11  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 108  
 Ser Met Gly Gln Glu Val Asp Arg Glu Leu Val  
   1                          5                  10  
 35           <210> 109  
           <211> 11  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 109  
 Ala Glu Asn Asp Gln Met Val Asp Trp Glu Ile  
   1                          5                  10  
 40           <210> 110  
           <211> 11

<212> PRT  
 <213> Human and artificial sequences

<400> 110

5 Gly Gly Trp Gln Glu Ser Asp Ile Pro Gly Arg  
 1 5 10

<210> 111

<211> 11

10 <212> PRT  
 <213> Human and artificial sequences

<400> 111

15 Gly Gly Trp Gln Glu Lys Asp Lys Glu Leu Arg  
 1 5 10

<210> 112

<211> 12

<212> PRT

20 <213> Human and artificial sequences

<400> 112

25 His Cys Cys Arg Ile Asp Arg Glu Val Ser Gly Ala  
 1 5 10

<210> 113

<211> 12

<212> PRT

<213> Human and artificial sequences

<400> 113

30 Cys Ala Pro Gly Met Gly Cys Trp Glu Ser Val Lys  
 1 5 10

<210> 114

<211> 17

<212> PRT

<213> Human and artificial sequences

<400> 114

40 Ser Cys Arg Glu Val Trp Leu Gly Gly Ser Glu Met Ile Met Asp Cys  
 1 5 10 15  
 Glu

<210> 115

<211> 17

<212> PRT

<213> Human and artificial sequences

<400> 115

50 Ser Cys Pro Ala Phe Pro Arg Glu Gly Asp Leu Cys Ala Pro Pro Thr  
 1 5 10 15  
 Val

<210> 116

<211> 17

<212> PRT

60 <213> Human and artificial sequences

<400> 116

65 Phe Cys Pro Glu Pro Ile Cys Ser Pro Pro Leu Ser Arg Met Thr Leu  
 1 5 10 15  
 Ser

5           <210> 117  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 117  
 Glu Cys Asn Gln Asn Leu Ser Gly Ser Leu Arg His Val Asp Leu Asn  
   1                          5                          10                          15  
 10   Cys  
  
 15           <210> 118  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 118  
 Arg Cys Asp Gln Gln Leu Pro Arg Asp Ser Tyr Thr Phe Cys Met Met  
   1                          5                          10                          15  
 20   Ser  
  
 25           <210> 119  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 119  
 His Cys Gln Gln Val Phe Phe Pro Gln Asp Tyr Leu Trp Cys Gln Arg  
   1                          5                          10                          15  
 30   Gly  
  
 35           <210> 120  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 120  
 Asp Cys Glu Glu Pro Met Cys Ser Pro Val Leu Leu Gln Lys Leu Lys  
   1                          5                          10                          15  
 40   Pro  
  
 45           <210> 121  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 121  
 Asn Cys Gln Asp Gln Met Leu Arg Glu Asp Ala Gly Cys Trp Ser Lys  
   1                          5                          10                          15  
 50   Ile  
  
 55           <210> 122  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 122  
 His Cys Glu Glu Pro Glu Tyr Ser Pro Ala Thr Arg Val Phe Cys Gly  
   1                          5                          10                          15  
 60   Arg  
  
 65           <210> 122  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 122  
 His Cys Glu Glu Pro Glu Tyr Ser Pro Ala Thr Arg Val Phe Cys Gly  
   1                          5                          10                          15  
 65   Arg

5           <210> 123  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 123  
 Asp Cys Asp Trp Ile Asn Pro Pro Asp Pro Pro His Phe Trp Lys Asp  
   1                          5                  10                  15  
 10 Thr

15           <210> 124  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 124  
 Ala Cys Phe Ser Arg Asn Gly Gln Val Thr Asp Val Pro His Ser Cys  
   1                          5                  10                  15  
 20 Tyr

25           <210> 125  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 125  
 Lys Cys Pro Thr Tyr Pro Lys Pro Asn Asp Arg Cys Leu Trp Pro Val  
   1                          5                  10                  15  
 30 Pro

35           <210> 126  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 126  
 Tyr Cys Pro Lys Tyr Pro Leu Glu Gly Asp Cys Leu Leu Asp Asn Asp  
   1                          5                  10                  15  
 40 Tyr

45           <210> 127  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 127  
 Arg Cys Glu Glu Trp Leu Cys Ile Pro Pro Ala Pro Ala Phe Ala Pro  
   1                          5                  10                  15  
 50 Pro

55           <210> 128  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequences  
  
           <400> 128  
 Thr Cys Gly Gln Ser Glu Leu Arg Cys Ala Ser Leu Glu Thr His His  
   1                          5                  10                  15  
 60 Val

<210> 129  
 <211> 16  
 <212> PRT  
 5 <213> Human and artificial sequences  
  
 <400> 129  
 Asn Cys Asn Asp Asn Pro Met Leu Asp Cys Met Pro Ala Trp Ser Ser  
 1 5 10 15  
 10  
 <210> 130  
 <211> 12  
 <212> PRT  
 15 <213> Human and artificial sequences  
  
 <400> 130  
 Asp Ala Leu Asp Glu Arg Ala Trp Arg Ala Arg Ala  
 1 5 10  
 20  
 <210> 131  
 <211> 12  
 <212> PRT  
 <213> Human and artificial sequences  
 25  
 <400> 131  
 Ser Cys Gln Gly Arg Glu Val Arg Arg Glu Cys Trp  
 1 5 10  
 30  
 <210> 132  
 <211> 12  
 <212> PRT  
 <213> Human and artificial sequences  
 35  
 <400> 132  
 Val Cys Asp Glu Cys Val Ser Arg Glu Leu Ala Leu  
 1 5 10  
 40  
 <210> 133  
 <211> 12  
 <212> PRT  
 <213> Human and artificial sequences  
 45  
 <400> 133  
 Trp Cys Leu Glu Pro Glu Cys Ala Pro Gly Leu Leu  
 1 5 10  
 50  
 <210> 134  
 <211> 12  
 <212> PRT  
 <213> Human and artificial sequences  
 55  
 <400> 134  
 Asp Cys Leu Ser Lys Gly Gln Met Ala Asp Leu Cys  
 1 5 10  
 60  
 <210> 135  
 <211> 12  
 <212> PRT  
 <213> Human and artificial sequences  
 65  
 <400> 135  
 Val Cys Asp Glu Cys Val Ser Arg Glu Leu Ala Leu  
 1 5 10  
 <210> 136  
 <211> 12

<212> PRT  
 <213> Human and artificial sequences  
  
 <400> 136  
 5 Gly Cys Pro Thr Trp Pro Arg Val Gly Asp His Cys  
   1                  5                  10  
  
 <210> 137  
 <211> 12  
 10 <212> PRT  
     <213> Human and artificial sequences  
  
 <400> 137  
 15 Arg Cys Gln Ser Ala Arg Val Val Pro Glu Cys Trp  
   1                  5                  10  
  
 <210> 138  
 <211> 12  
 20 <212> PRT  
     <213> Human and artificial sequences  
  
 <400> 138  
 25 Ser Cys Ala Pro Ser Gly Asp Cys Gly Tyr Lys Gly  
   1                  5                  10  
  
 <210> 139  
 <211> 12  
 30 <212> PRT  
     <213> Human and artificial sequences  
  
 <400> 139  
 35 Gly Cys Pro Met Trp Pro Gln Pro Asp Asp Glu Cys  
   1                  5                  10  
  
 <210> 140  
 <211> 12  
 40 <212> PRT  
     <213> Human and artificial sequences  
  
 <400> 140  
 45 Glu Cys Pro Arg Trp Pro Leu Met Gly Asp Gly Cys  
   1                  5                  10  
  
 <210> 141  
 <211> 12  
 50 <212> PRT  
     <213> Human and artificial sequences  
  
 <400> 141  
 55 Gly Cys Gln Val Gly Glu Leu Val Trp Cys Arg Glu  
   1                  5                  10  
  
 <210> 142  
 <211> 12  
 60 <212> PRT  
     <213> Human and artificial sequences  
  
 <400> 142  
 65 Gln Cys Val Arg Asp Gly Thr Arg Lys Val Cys Met  
   1                  5                  10  
  
 <210> 143  
 <211> 12  
 <212> PRT  
 <213> Human and artificial sequences



<400> 143  
 Thr Cys Leu Val Asp Arg Gln Glu Ser Asp Val Cys  
 1 5 10

5 <210> 144  
 <211> 12  
 <212> PRT  
 <213> Human and artificial sequences

10 <400> 144  
 Asp Cys Val Val Asp Gly Asp Arg Leu Val Cys Leu  
 1 5 10

15 <210> 145  
 <211> 12  
 <212> PRT  
 <213> Human and artificial sequences

20 <400> 145  
 Arg Cys Glu Gln Gly Ala Leu Arg Cys Val Gly Glu  
 1 5 10

25 <210> 146  
 <211> 12  
 <212> PRT  
 <213> Human and artificial sequences

30 <400> 146  
 Val Cys Pro Pro Gly Trp Lys Asn Leu Gly Cys Asn  
 1 5 10

35 <210> 147  
 <211> 12  
 <212> PRT  
 <213> Human and artificial sequences

40 <400> 147  
 Met Cys Gln Gly Trp Glu Ile Val Ser Glu Cys Trp  
 1 5 10

45 <210> 148  
 <211> 25  
 <212> PRT  
 <213> Human and artificial sequences

50 <400> 148  
 Ala Asp Gly Ala Gly Cys Phe Met Asn Lys Gln Met Ala Asp Leu Glu  
 1 5 10 15  
 Leu Cys Pro Arg Glu Ala Ala Glu Ala  
 20 25

55 <210> 149  
 <211> 25  
 <212> PRT  
 <213> Human and artificial sequences

60 <400> 149  
 Ala Asp Gly Ala Gly Cys Phe Met Asn Lys Gln Met Ala Asp Leu Glu  
 1 5 10 15  
 Leu Cys Pro Arg Thr Ala Ala Glu Ala  
 20 25

65 <210> 150  
 <211> 25  
 <212> PRT  
 <213> Human and artificial sequences

5           <400> 150  
           Ala Asp Gly Ala Ala Cys Phe Met Asn Lys Gln Met Ala Asp Leu Glu  
           1                           5                           10                           15  
           Leu Cys Pro Arg Val Ala Ala Glu Ala  
                           20                           25

10           <210> 151  
           <211> 25  
           <212> PRT  
           <213> Human and artificial sequences

15           <400> 151  
           Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Leu Ala Asp Leu Glu  
           1                           5                           10                           15  
           Leu Cys Pro Arg Val Ala Ala Glu Ala  
                           20                           25

20           <210> 152  
           <211> 25  
           <212> PRT  
           <213> Human and artificial sequences

25           <400> 152  
           Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Leu Ala Asp Leu Glu  
           1                           5                           10                           15  
           Leu Cys Pro Arg Glu Ala Ala Glu Ala  
                           20                           25

30           <210> 153  
           <211> 25  
           <212> PRT  
           <213> Human and artificial sequences

35           <400> 153  
           Ala Asp Gly Ala Gly Cys Phe Met Asn Lys Gln Leu Ala Asp Leu Glu  
           1                           5                           10                           15  
           Met Cys Pro Arg Asp Asp Ala Glu Ala  
                           20                           25

40           <210> 154  
           <211> 25  
           <212> PRT  
           <213> Human and artificial sequences

45           <400> 154  
           Ala Asp Gly Ala Gly Cys Phe Met Asn Lys Gln Leu Ala Asp Pro Glu  
           1                           5                           10                           15  
           Leu Cys Pro Arg Glu Ala Glu Glu Ala  
                           20                           25

50           <210> 155  
           <211> 25  
           <212> PRT  
           <213> Human and artificial sequences

55           <400> 155  
           Ala Asp Gly Ala Gly Cys Phe Met Asn Lys Gln Leu Val Asp Leu Glu  
           1                           5                           10                           15  
           Leu Cys Pro Arg Gly Ala Ala Glu Ala  
                           20                           25

60           <210> 156  
           <211> 25  
           <212> PRT  
           <213> Human and artificial sequences

<400> 156  
 Ala Asp Gly Ala Gly Cys Phe Met Asn Asn Gln Leu Ala Asp Trp Glu  
 1 5 10 15  
 5 Leu Cys Pro Arg Ala Ala Ala Glu Ala  
 20 25

<210> 157  
 <211> 25  
 <212> PRT  
 <213> Human and artificial sequences

<400> 157  
 Ala Asp Gly Ala Gly Cys Phe Met Asn Lys Gln Met Ala Asp Trp Glu  
 1 5 10 15  
 15 Met Cys Pro Arg Ala Ala Ala Glu Ala  
 20 25

<210> 158  
 <211> 25  
 <212> PRT  
 <213> Human and artificial sequences

<400> 158  
 Ala Asp Gly Ala Gly Cys Phe Met Asn Lys Gln Gln Ala Asp Leu Glu  
 1 5 10 15  
 25 Leu Cys Pro Arg Gly Ala Ala Glu Ala  
 20 25

<210> 159  
 <211> 25  
 <212> PRT  
 <213> Human and artificial sequences

<400> 159  
 Ala Asp Gly Ala Glu Cys Phe Met Asn Lys Gln Leu Ala Asp Ser Glu  
 1 5 10 15  
 35 Leu Cys Pro Arg Val Ala Ala Glu Ala  
 20 25

<210> 160  
 <211> 25  
 <212> PRT  
 <213> Human and artificial sequences

<400> 160  
 Ala Asp Gly Ala Gly Cys Phe Met Asn Lys Gln Leu Ala Asp Leu Glu  
 1 5 10 15  
 45 Leu Cys Pro Arg Glu Ala Ala Glu Ala  
 20 25

<210> 161  
 <211> 25  
 <212> PRT  
 <213> Human and artificial sequences

<400> 161  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Met Gln Met Ala Asp Gln Glu  
 1 5 10 15  
 55 Leu Cys Pro Arg Ala Ala Ala Glu Ala  
 20 25

<210> 162  
 <211> 25  
 <212> PRT  
 <213> Human and artificial sequences

<400> 162  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ser Asp Phe Glu  
 1 5 10 15  
 5 Leu Cys Pro Arg Glu Ala Gly Glu Ala  
 20 25  
  
 <210> 163  
 <211> 25  
 10 <212> PRT  
 <213> Human and artificial sequences  
  
 <400> 163  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu  
 1 5 10 15  
 15 Leu Cys Thr Arg Glu Ala Ala Glu Ala  
 20 25  
  
 <210> 164  
 <211> 25  
 20 <212> PRT  
 <213> Human and artificial sequences  
  
 <400> 164  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu  
 1 5 10 15  
 25 Leu Cys Pro Arg Gln Ala Ala Glu Ala  
 20 25  
  
 <210> 165  
 <211> 25  
 30 <212> PRT  
 <213> Human and artificial sequences  
  
 <400> 165  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Asn Gln Met Ala Asp Leu Glu  
 1 5 10 15  
 35 Leu Cys Pro Arg Gly Gly Ala Glu Ala  
 20 25  
  
 <210> 166  
 <211> 25  
 40 <212> PRT  
 <213> Human and artificial sequences  
  
 <400> 166  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Trp Glu  
 1 5 10 15  
 50 Leu Cys Pro Arg Glu Gly Ala Glu Ala  
 20 25  
  
 <210> 167  
 <211> 25  
 55 <212> PRT  
 <213> Human and artificial sequences  
  
 <400> 167  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu  
 1 5 10 15  
 60 Leu Cys Pro Ser Gln Ala Ala Glu Ala  
 20 25  
  
 <210> 168  
 <211> 25  
 65 <212> PRT  
 <213> Human and artificial sequences

<400> 168  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu  
 1 5 10 15  
 5 Leu Cys Pro Arg Glu Gly Ala Glu Ala  
 20 25  
  
 <210> 169  
 <211> 25  
 10 <212> PRT  
 <213> Human and artificial sequences  
  
 <400> 169  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Ser Glu  
 1 5 10 15  
 15 Leu Cys Pro Arg Glu Pro Ala Glu Ala  
 20 25  
  
 <210> 170  
 <211> 25  
 20 <212> PRT  
 <213> Human and artificial sequences  
  
 <400> 170  
 Ala Asp Gly Ala Gly Cys Phe Ile Lys Lys Gln Met Ala Asp Leu Glu  
 1 5 10 15  
 25 Leu Cys Pro Arg Glu Ala Trp Glu Ala  
 20 25  
  
 <210> 171  
 <211> 25  
 30 <212> PRT  
 <213> Human and artificial sequences  
  
 <400> 171  
 Ala Asp Gly Ala Glu Cys Phe Ile Asn Lys Gln Met Ala Asp Arg Glu  
 1 5 10 15  
 35 Leu Cys Ala Arg Glu Val Ala Glu Ala  
 20 25  
  
 <210> 172  
 <211> 25  
 <212> PRT  
 <213> Human and artificial sequences  
 45  
  
 <400> 172  
 Ala Asp Gly Ala Gly Cys Phe Ile Asp Lys Gln Met Ala Asp Leu Glu  
 1 5 10 15  
 50 Leu Cys Pro Arg Ala Ala Ala Glu Ala  
 20 25  
  
 <210> 173  
 <211> 25  
 <212> PRT  
 55 <213> Human and artificial sequences  
  
 <400> 173  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu  
 1 5 10 15  
 60 Leu Cys Arg Arg Glu Ala Gly Glu Ala  
 20 25  
  
 <210> 174  
 <211> 25  
 65 <212> PRT  
 <213> Human and artificial sequences

<400> 174  
 Ala Asp Gly Ala Gly Cys Phe Lys Asn Lys Gln Met Val Asp Ser Glu  
 1 5 10 15  
 5 Leu Cys Ala Arg Gln Ala Ala Glu Ala  
 20 25  
  
 <210> 175  
 <211> 25  
 10 <212> PRT  
 <213> Human and artificial sequences  
  
 <400> 175  
 Ala Asp Gly Ala Gly Cys Phe Gln Asn Lys Gln Met Ala Asp Leu Glu  
 1 5 10 15  
 15 Leu Cys Pro Arg Glu Ala Ala Glu Ala  
 20 25  
  
 <210> 176  
 <211> 25  
 20 <212> PRT  
 <213> Human and artificial sequences  
  
 <400> 176  
 Ala Asp Gly Ala Glu Cys Phe Ile Asn Lys Gln Arg Ala Asp Leu Glu  
 1 5 10 15  
 25 Leu Cys Pro Gly Glu Ala Ala Glu Ala  
 20 25  
  
 <210> 177  
 <211> 25  
 30 <212> PRT  
 <213> Human and artificial sequences  
  
 <400> 177  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Ser Glu  
 1 5 10 15  
 35 Leu Cys Pro Ala Ala Ala Ala Glu Ala  
 20 25  
  
 <210> 178  
 <211> 25  
 40 <212> PRT  
 <213> Human and artificial sequences  
  
 <400> 178  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Arg Gln Met Ala Asp Pro Glu  
 1 5 10 15  
 45 50 Leu Cys Pro Arg Glu Ala Ala Glu Ala  
 20 25  
  
 <210> 179  
 <211> 25  
 55 <212> PRT  
 <213> Human and artificial sequences  
  
 <400> 179  
 Ala Asp Gly Ala Gly Cys Phe Ile Glu Lys Gln Met Ala Asp Met Glu  
 1 5 10 15  
 60 Leu Cys Gln Ala Arg Ala Ala Glu Ala  
 20 25  
  
 <210> 180  
 <211> 25  
 65 <212> PRT  
 <213> Human and artificial sequences

<400> 180  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Trp Glu  
 1 5 10 15  
 5 Leu Cys Pro Arg Glu Ala Ala Glu Ala  
 20 25  
  
 <210> 181  
 <211> 25  
 10 <212> PRT  
 <213> Human and artificial sequences  
  
 <400> 181  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Asn Gln Met Ala Asp Leu Glu  
 1 5 10 15  
 15 Leu Cys Pro Arg Glu Ala Ala Glu Ala  
 20 25  
  
 <210> 182  
 <211> 25  
 20 <212> PRT  
 <213> Human and artificial sequences  
  
 <400> 182  
 Ala Asp Gly Ala Gly Cys Phe Ile Glu Lys Gln Met Ala Asp Met Glu  
 1 5 10 15  
 25 Leu Cys Gln Arg Glu Thr Ala Glu Ala  
 20 25  
  
 <210> 183  
 <211> 25  
 30 <212> PRT  
 <213> Human and artificial sequences  
  
 <400> 183  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Met Glu  
 1 5 10 15  
 35 Leu Cys Pro Arg Glu Ala Ala Glu Ala  
 20 25  
  
 <210> 184  
 <211> 25  
 <212> PRT  
 <213> Human and artificial sequences  
 45  
 <400> 184  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu  
 1 5 10 15  
 50 Leu Cys Pro Arg Glu Ala Ala Glu Ala  
 20 25  
  
 <210> 185  
 <211> 25  
 <212> PRT  
 55 <213> Human and artificial sequences  
  
 <400> 185  
 Ala Asp Gly Ala Gly Cys Phe Arg Asn Lys Gln Met Ala Asp Leu Glu  
 1 5 10 15  
 60 Leu Cys Pro Arg Glu Ala Ala Glu Ala  
 20 25  
  
 <210> 186  
 <211> 25  
 65 <212> PRT  
 <213> Human and artificial sequences

<400> 186  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu  
 1 5 10 15  
 5 Leu Cys Pro Ala Arg Ala Ala Glu Ala  
 20 25  
 <210> 187  
 <211> 25  
 10 <212> PRT  
 <213> Human and artificial sequences  
 <400> 187  
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Arg Gln Leu Ala Asp Met Glu  
 1 5 10 15  
 15 Leu Cys Ser Arg Gly Ala Ala Glu Ala  
 20 25  
 <210> 188  
 20 <211> 25  
 <212> PRT  
 <213> Human and artificial sequences  
 <400> 188  
 25 Ala Asp Gly Ala Glu Cys Phe Ile Asn Arg Gln Met Ala Asp Leu Glu  
 1 5 10 15  
 Leu Cys Gly Arg Glu Ala Ala Glu Ala  
 20 25  
 30 <210> 189  
 <211> 25  
 <212> PRT  
 <213> Human and artificial sequences  
 35 <400> 189  
 Ala Asp Gly Ala Gly Cys Phe Ile Ser Pro Gln Leu Ala Asp Trp Lys  
 1 5 10 15  
 Arg Cys Met Arg Glu Ala Ala Glu Ala  
 20 25  
 40 <210> 190  
 <211> 25  
 <212> PRT  
 <213> Human and artificial sequences  
 45 <400> 190  
 Ala Asp Gly Ala Gly Cys Ser Ile His Thr Gln Met Ala Asp Trp Glu  
 1 5 10 15  
 50 Arg Cys Leu Arg Glu Gly Ala Glu Ala  
 20 25  
 <210> 191  
 <211> 25  
 <212> PRT  
 55 <213> Human and artificial sequences  
 <400> 191  
 Ala Asp Gly Ala Gly Cys Ser Ile His Arg Gln Met Ala Asp Trp Glu  
 1 5 10 15  
 60 Arg Cys Leu Arg Glu Gly Ala Glu Ala  
 20 25  
 <210> 192  
 <211> 16  
 65 <212> PRT  
 <213> Human and artificial sequences



<400> 192  
 Cys Ser Ser Cys Asp Gly Gly Gly His Lys Pro Pro Thr Ile Gln Cys  
 1 5 10 15

5

<210> 193  
 <211> 20  
 <212> PRT  
 <213> Human and artificial sequences

10

<400> 193  
 Cys Leu Gln Ser Ser Cys Asp Gly Gly Gly His Phe Pro Pro Thr Ile  
 1 5 10 15

15

Gln Leu Leu Cys  
 20